Potential Drug-Drug Interaction (PDDI) CDS IG : STU1 Ballot 2, published by HL7 Clinical Decision Support Workgroup. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/PDDI-CDS/ and changes regularly. See the Directory of published versions
Draft as of 2018-07-02 |
{
"resourceType" : "ValueSet",
"id" : "valueset-nepafenac-exclude",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul><li>Include these codes as defined in <a href=\"http://www.nlm.nih.gov/research/umls/rxnorm\"><code>http://www.nlm.nih.gov/research/umls/rxnorm</code></a><table class=\"none\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td>603978</td><td>nepafenac 1 MG/ML Ophthalmic Suspension [Nevanac]</td></tr><tr><td>1365866</td><td>nepafenac 3 MG/ML Ophthalmic Suspension [Ilevro]</td></tr><tr><td>603977</td><td>nepafenac Ophthalmic Suspension [Nevanac]</td></tr><tr><td>1365864</td><td>nepafenac Ophthalmic Suspension [Ilevro]</td></tr><tr><td>578044</td><td>nepafenac 1 MG/ML Ophthalmic Suspension</td></tr><tr><td>1362132</td><td>nepafenac 3 MG/ML Ophthalmic Suspension</td></tr><tr><td>578043</td><td>nepafenac Ophthalmic Suspension</td></tr><tr><td>1158407</td><td>nepafenac Ophthalmic Product</td></tr><tr><td>1365865</td><td>Ilevro Ophthalmic Product</td></tr><tr><td>1182860</td><td>Nevanac Ophthalmic Product</td></tr></table></li></ul></div>"
},
"url" : "http://hl7.org/fhir/uv/pddi/ValueSet/valueset-nepafenac-exclude",
"version" : "1.0.0-ballot",
"name" : "Valueset_nepafenac_exclude",
"title" : "Exclude Nepafenac Medications Value Set",
"status" : "draft",
"experimental" : true,
"date" : "2018-07-02",
"publisher" : "HL7 Clinical Decision Support Workgroup",
"contact" : [
{
"telecom" : [
{
"system" : "url",
"value" : "http://hl7.org/Special/committees/dss"
}
]
}
],
"description" : "ValueSet containing drug identifiers to exclude. Criteria is explicitly stating topical, gel, cream, ointment, otic, or ophthalmic formulations.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code" : "001"
}
]
}
],
"purpose" : "To refine valueset for Warfarin + NSAID PDDI-CDS",
"copyright" : "(copyright expectations unknown)",
"compose" : {
"include" : [
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"concept" : [
{
"code" : "603978",
"display" : "nepafenac 1 MG/ML Ophthalmic Suspension [Nevanac]"
},
{
"code" : "1365866",
"display" : "nepafenac 3 MG/ML Ophthalmic Suspension [Ilevro]"
},
{
"code" : "603977",
"display" : "nepafenac Ophthalmic Suspension [Nevanac]"
},
{
"code" : "1365864",
"display" : "nepafenac Ophthalmic Suspension [Ilevro]"
},
{
"code" : "578044",
"display" : "nepafenac 1 MG/ML Ophthalmic Suspension"
},
{
"code" : "1362132",
"display" : "nepafenac 3 MG/ML Ophthalmic Suspension"
},
{
"code" : "578043",
"display" : "nepafenac Ophthalmic Suspension"
},
{
"code" : "1158407",
"display" : "nepafenac Ophthalmic Product"
},
{
"code" : "1365865",
"display" : "Ilevro Ophthalmic Product"
},
{
"code" : "1182860",
"display" : "Nevanac Ophthalmic Product"
}
]
}
]
}
}